Skip to main content

Currently Skimming:

1 Introduction and Overview
Pages 1-4

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 1...
... These collaborative efforts make it possible to identify new drug targets, enhance the understanding of the underlying basis of disease, discover novel indications for the use of already approved products, and develop biomarkers for disease outcomes or directed drug use. Partnerships can also reduce duplicative efforts and create a much more efficient, robust, and successful system for translating discoveries into health care applications by sharing unique resources and expertise among participants.
From page 2...
... The committee's 2009 report called for striking a balance between protecting against financial conflicts and advancing the generation of knowledge that benefits society. However, some public and private institutions have adopted strict conflict of interest policies, leading to difficulties in establishing collaborative efforts, to challenges in gaining access to external scientific expertise, and to restricted interactions and communications between industry representatives and health care providers (Zinner et al., 2010)
From page 3...
... .2 A wide range of stakeholders, including government officials, pharmaceutical company representatives, academic administrators and researchers, health care providers, medical ethicists, patient advocates, and consumers, were invited to present their perspectives and participate in discussions during the workshop. All individuals and organizations have conflicts, regardless of the kind of work they are doing, said Allen Lichter, chief executive officer of the American Society of Clinical Oncology (ASCO)
From page 4...
... A discussion of issues that arise when serving on advisory committees and when recruiting consulting experts for government work is also addressed. Chapter 4 examines how public descriptions of conflicts of interest, including reporting on the issue, shape the perceptions of policy makers, patients, and the broader public.

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.